Literatuurlijst Somatische aspecten

• Adab, N., Jacoby, A., Smith, D., & Chadwick, D. (2001). Additional educational needs in children born to mothers with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry, 70, 15-21.
• Akkerhuis, G.W., & Nolen, W.A. (2003). Lithium-associated psoriasis and omega-3 fatty acids. American Journal of Psychiatry, 160, 1355.
• Aiken, C.B., & Orr, C. (2010). Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature. Psychiatry (Edgmont), 7, 27-32.
• Aizenberg, D., Sigler, M., Zemishlany, Z., & Weizman, A. (1996). Lithium and male sexual function in affective patients. Clinical Neuropharmacology, 19, 515-9.
• Alphen, C. van, Ammeraal, M., Blanke, C., Boonstra, N., Boumans, H., Bruggeman, R., e.a. (2012). Multidisciplinaire richtlijn schizofrenie. Utrecht: De Tijdstroom Uitgeverij.
• Askmark, H., & Wiholm, B.E. (1990). Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurologica Scandinavica, 81, 131-40.
• Baek, J.H., Kinrys, G., & Nierenberg, A.A. (2014). Lithium tremor revisited: pathophysiology and treatment. Acta Psychiatrica Scandinavica, 129, 17-23.
• Barrueto, F. Jr., & Hack, J.B. (2001) Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy. Academic emergency Medicine, 8, 999-1001.
• Battle, D.C., Von Riotte, A.B., Gaviria, M., & Grupp, M. (1985). Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. New England Journal of Medicine, 312, 408-414.
• Bedford, J.J., Weggery, S., Ellis, G., McDonald, F.J., Joyce, P.R., Leader, J.P., e.a. (2008). Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clinical Journal of the American Society of Nephrology, 3, 13241331.
• Bendz, H., & Aurell, M. (1999). Drug-induced diabetes insipidus: incidence, prevention and management. Drug Safety, 21, 449-456.
• Bendz, H., Aurell, M., & Lanke, J. (2001). A historical cohort study of kidney damage in long-term lithium patients: continued surveillance needed. European Psychiatry, 16, 199-206.
• Bertolino, J.G. (1990). Carbamazepine: What physicians should know about its hematologic effects. Postgraduate Medicine, 88, 183-186.
• Beus, E. de, & Rookmaaker, M.B. (2013). Richtlijn renale bijwerkingen chronisch lithiumgebruik. Raadpleegbaar via: http://www.nefrovisie.nl/wp-content/ uploads/2014/02/Lithiumrichtlijn-definitief-2013.pdf. Nieuwegein: Nederlandse Federatie voor Nefrologie.
• Bobo, W.V., Cooper, W.O., Stein, C.M., Olfson, M., Graham, D., Daugherty, J., e.a. (2013). Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 70, 1067-1075.
• Bocchetta, A., & Loviselli, A. (2006). Lithium treatment and thyroid abnormalities. Clinical Practice and Epidemiology in Mental Health, 2, 23.
• Boton, R., Gaviria, M., & Batlle, D.C. (1987). Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. American Journal of Kidney Diseases, 10, 329-345.
• Bowden, C.L. (2003). Valproate. Bipolar Disorders, 5, 189-202.
• Bowden, C. L., Brugger, A. M., Swann, A. C., Calabrese, J. R., Janicak, P.G., Petty, F., e.a. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA, 271, 918-24.
• Bowden, C.L., Calabrese, J.R., Mcelroy, S.L., Gyulai, L., Wassef, A., Petty, F., e.a. (2000). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archives of General Psychiatry, 57, 481-489.
• Burgess, A., Geddes, J., Hwaton, K., Townsend, E., Jamison, K., & Goodwin, G. (2001). Lithium for maintenance treatment of mood disorders. Cochrane Database of Systematic Reviews 2001(3), Article CD003013. The Cochrane Library Database.
• Cahn, W., Ramlal, D., Bruggeman, R., Haan, L. de, Scheepers, F.E., Soest, M.M. van, e.a. (2008). Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. Tijdschrift voor Psychiatrie, 50, 579-591.
• Calabrese, J.R., Sullivan, J.R., Bowden, C.L., Suppes, T., Goldberg, J.F., Sachs, G.S., e.a. (2002). Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. Journal of Clinical Psychiatry, 63, 10121019.
• Campbell, E., Kennedy, F., Russell, A., Smithson, W.H., Parsons, L., Morrison, P.J., e.a. (2014). Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology, Neurosurgery and Psychiatry, 85, 1029-1034.
• CBG (2014). Aangescherpte waarschuwing: valproaat (waaronder Depakine, Propymal, Orfiril) verhoogt de kans op afwijkingen foetus [internetpagina]. Utrecht: College ter Beoordeling van Geneesmiddelen. Raadpleegbaar via: http://www.cbg-meb.nl/CBG/nl/humane-geneesmiddelen/actueel/141222_ DHPC_valproaat/default.htm.
• Chicharro, A.V., De Marinis, A.J., & Kanner, A.M. (2007). The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist? Epilepsy and Behavior, 11, 361-366.
• Citrome, L. (2013). A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs, 27, 879-910.
• Citrome, L., Ketter, T.A., Cucchiaro, J., & Loebel, A. (2014). Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 155, 20-27.
• Clozapine Plus Werkgroep (2013). Richtlijn voor het gebruik van clozapine. Heerhugowaard: Clozapine Plus Werkgroep. Raadpleegbaar via: www.clozapinepluswerkgroep.nl/publicaties/richtlijn-voor-het-gebruik-van-clozapine.
• Cohen, L.S. (2007). Treatment of bipolar disorder during pregnancy. Journal of Clinical Psychiatry, 68(Suppl 9), 4-9.
• Cohen, L.S., Friedman, J.M., Jefferson, J.W., Johnson, E.M., & Weiner, M.L.A. (1994). Reevaluation of risk of in-utero exposure to lithium. JAMA, 271, 146-150.
• Cunnington, M.C., Weil, J.G., Messenheimer, J.A., Ferber, S., Yerby, M., & Tennis, P. (2011). Final results from 18 years of the International Lamotrigine  Pregnancy Registry. Neurology, 76, 1817-1823.
• Daban, C., Martínez-Arán, A., Torrent, C., Sanchez-Moreno, J., Goikolea, J.M., Benabarre, A., e.a. (2006). Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. Journal of Clinical Psychopharmacology, 26, 178-181.
• Darbà, J., Kaskens, L., Aranda, P., Arango, C., Bobes, J., Carmena, R., & Rejas, J. (2013). A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs. Annals of Clinical Psychiatry, 25, 17-26.
• De Hert, M., Dekker, J.M., Wood, D., Kahl, K.G., Holt, R.I., & Möller, H.J. (2009). Cardiovascular disease and diabetes in people with severe mental illness: Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry, 24, 412-424.
• De Hert, M., Dobbelaere, M., Sheridan, E.M., Cohen, D., & Correll, C.U. (2011). Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry, 26, 144-158.
• De Hert, M., Yu, W., Detraux, J., Sweers, K., Winkel, R. van, & Correll, C.U. (2012). Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs, 26, 733-759.
• Dealberto, M.J. (2007).Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. International Clinical Psychopharmacology, 22, 330-337.
• Deligiannidis, K.M., Byatt, N., & Freeman, M.P. (2014). Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. Journal of  Clinical Psychopharmacology, 34, 244-255.
• Diaz, V.V., Balanzá-Martinez, V., Soeiro-de-Souza, M.G., Moreno, R.A., Figueira, M.L., Machado-Vieira, R., e.a. (2012). Pharmalogical approaches in bipolar disorders and the impact on cognition: a critical review. Acta Psychiatrica Scandinavica, 126, 315-331.
• Dols, A., Sienaert, P., Gerven, H. van, Schouws, S., Stevens, A., Kupka, R., & Stek, M.L. (2013). The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: a review. International Clinical Psychopharmacology, 28, 287-296.
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285, 2486-2497.
• Findling, R.L., Landersdorfer, C.B., Kafantaris, V., Pavuluri, M., McNamara, N.K., McClellan, J., e.a. (2010). First-dose pharmacokinetics of lithium carbonate in children and adolescents. Journal of Clinical Psychopharmacology, 30, 404-410.
• Gareri, P., Segura-García, C., Manfredi, V.G., Bruni, A., Ciambrone, P., Cerminara, G., e.a. (2014). Use of atypical antipsychotics in the elderly: a clinical review. Clinical Interventions in Aging, 9, 1363-1373.
• Gau, C.S., Chang, C.J., Tsai, F.J., Chao, P.F., & Gau, S.S. (2010). Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched case-control study. Bipolar Disorders, 12, 253-263.
• Gelenberg, A.J., & Jefferson, J.W. (1995). Lithium tremor. Journal of Clinical Psychiatry, 56, 283-287.
• Geeraerts, I., & Sienaert, P. (2013). Schattingsmethoden versus klinische titratie bij het opstarten van lithium; een systematisch overzicht Tijdschrift voor Psychiatrie, 55, 761-771.
• Gerhard, T., Huybrechts, K., Olfson, M., Schneeweiss, S., Bobo, W.V., Doraiswamy, P.M., e.a. (2014). Comparative mortality risks of antipsychotic medications in community-dwelling older adults. British Journal of  Psychiatry, 205, 44-51.
• Ghose, K. (1991). The need for a review journal of drug use and the elderly.  Drugs and Aging, 1, 2-5.
• Ghozzi, H., Hakim, A., Sahnoun, Z., Ben Mahmoud, L., Atheymen, R., Hammami, S., e.a. (2011). Relation entre les concentrations plasmatiques d’acide valproïque et la survenue d’une hépatotoxicité [Relationship between plasma concentrations of valproic acid and hepatotoxicity in patients receiving high doses]. Revue Neurologique, 167, 600-606.
• Goodwin, F.K., Jamison, K.R., & Ghaemi, S.N. (2007). Manic-depressive illness: bipolar disorders and recurrent depression. New York: Oxford University Press.
• Hallam, K.T. (2010). Managing the impact of mood stabiliser-induced tremors in patients with bipolar disorder. Acta NeuroPsychiatrica, 22, 259-260.
• Harden, C.L. (2008). Sexual dysfunction in women with epilepsy. Seizure, 17, 131-135.
• Hasnain, M., Vieweg, W.V., & Hollett, B. (2012). Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgraduate Medicine, 124, 154-167.
• Hetrick, S., Merry, S., McKenzie, J., Sindahl, P., & Proctor, M. (2007). Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews 2007(3), Article CD004851. The Cochrane Library Database.
• Hillemacher, T., Bleich, S., Kornhuber, J., & Frieling, H. (2006). Hair loss as a side effect of lamotrigine treatment. American Journal of Psychiatry, 163, 1451. Hoogd, S. de, Overbeek, W.A., Heerdink, E.R., Correll, C.U., Graeff, E.R. de, & Staal, W.G. (2012). Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics. Journal of Child and Adolescent Psychopharmacology, 22, 166-173. PMID: 22506734.
• Hung, C.C., Li, T.M., Wei, I.H., & Huang, C.C. (2011). The real mechanism of VPA-induced hyperammonemia remains unknown. General Hospital Psychiatry, 33, 84e3-4.
• Jafferany, M. (2008). Lithium and skin: dermatologic manifestations of lithium therapy. International Journal of Dermatology, 47, 1101-1110.
• Jansen, P.A.F. (1999). Atypische antipsychotica bij ouderen. COBO-Bulletin, 32, 39-42.
• Jansen, P.A.F. (2000). Valkuilen bij medicatiegebruik door ouderen. GeneesmiddelenBulletin, 34, 1.
• Jentink, J., Dolk, H., Loane, M.A., Morris, J.K., Wellesley, D., Garne, E., e.a. (2010a). Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ, 341, c6581.
• Jentink, J., Loane, M.A., Dolk, H., Barisic, I., Garne, E., Morris, J.K., & e.a. (2010b). Valproic acid monotherapy in pregnancy and major congenital malformations. New England Journal of Medicine, 362, 2185-2193.
• Jerrell, J.M. (2010). Neurological and cardiovascular adverse events associated with antimanic treatment in children and adolescents. CNS Neuroscience and Therapeutics, 16, 25-31. PMID: 19769597.
• Joffe, R.T., MacDonald, C., & Kutcher, S.P. (1988). Lack of differential cognitive effects of lithium and carbamazepine in bipolar affective disorder. Journal of Clinical Psychopharmacology, 8, 425-428.
• Jones, K.L., Lacro, R.V., Johnson, K.A., & Adams, J. (1989). Pattern of malformations in the children of women treated with carbamazepine during pregnancy. New England Journal of Medicine, 320, 1661-1666.
• Jong, L.T.W. de, & Kolling, P. (2011). Antipsychotica tijdens de zwangerschap. Geneesmiddelen Bulletin, 4, 37-43.
• Keck, P.E., & McElroy, S.L. (2003). Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. Journal of Clinical Psychiatry, 64, 1426-1435.
• Kirov, G., Tredget, J., John, R., Owen, M.J., & Lazarus, J.H. (2005). A crosssectional and a prospective study of thyroid disorders in lithium-treated patients. Journal of Affective Disorders, 87, 313-317.
• Kleiner, J., Altshuler, L., Hendrick, V., & Hershman, J.M. (1999). Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. Journal of Clinical Psychiatry, 60, 249-255.
• Konz, H.W., Meesters, P.D., Paans, N.P., Grootheest, D.S. van, Comijs, H.C., Stek, M.L., e.a. (2014). Screening for metabolic syndrome in older patients with severe mental illness. American Journal of Geriatric Psychiatry, 22, 11161120.
• Kupfer, D.J. (2005). The increasing medical burden in bipolar disorder. JAMA, 293, 2528-2530.
• Labiner, D.M. (2002). Lamotrigine and rash: scratching beneath the surface. Journal of Clinical Psychiatry, 63, 1010-1011.
• Lackman, G.M. (2004). Valproic-acid-induced thrombocytopenia and hepatotoxicity: discontinuation of treatment? Pharmacology, 70, 57-58.
• Lepkifker, E., Sverdlik, A., Iancu, I., Ziv, R., Segev, S., & Kotler, M. (2004). Renal insufficiency in long-term lithium treatment. Journal of Clinical Psychiatry, 65, 850-856.
• Lieshout, J. van, Felix-Schollaart, B., Bolsius, E.J.M., Boer, A.M., Burgers, J.S., Bouma, M., e.a. (2013). NHG-Standaard Schildklieraandoening, tweede herziening. Huisarts en Wetenschap, 56, 320-330.
• Licht, R.W., Vestergaard, P., Kessing, L.V., Larsen, J.K., & Thomsen, P.H. (2003). Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatrica Scandinavica Supplementum, 1-22.
• Malhi, G.S., & Tanious, M. (2011). Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs, 25, 289-298.
• Markowitz, G.S., Radhakrishnan, J., Kambham, N., Valeri, A.M., Hines, W.H., & D’Agati, V.D. (2000). Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. Journal of the American Society of Nephrology, 11, 1439-1448.
• McHenry, C.R., & Lee, K. (1996). Lithium therapy and disorders of the parathyroid glands. Endocrine Practice, 2, 103-109.
• McKinney, P.A., Finkenbine, R.D., & Devane, C.L. (1996). Alopecia and mood stabilizer therapy. Annals of Clinical Psychiatry, 8, 183-5.
• McKnight, R.F., Adida, M., Budge, K., Stockton, S., Goodwin, G.M., & Geddes, J.R. (2012). Lithium toxicity profile: a systematic review and meta-analysis. Lancet, 379, 721-728.
• Meeuwissen, J., Meijel, B. van, Gool, R. van, & Hermens, M.; Werkgroep Richtlijnontwikkeling Algemene somatische screening & Leefstijl (2015). Richtlijn somatische screening bij mensen met een ernstige psychische aandoening. Utrecht: Trimbos-instituut/V&VN.
• Mercke. Y., Sheng, H., Khan, T., & Lippmann, S. (2000). Hair loss in psychopharmacology. Annals of Clinical Psychiatry, 12, 35-42.
• Miodownik, C., Witztum, E., & Lerner, V. (2002). Lithium-induced tremor treated with vitamin B6: a preliminary case series. International Journal of Psychiatry in Medicine, 32, 103-108.
• Nadebaum, C., Anderson, V., Vadja, F., Reutens, D., & Wood, A. (2012). Neurobehavioral Consequences of Prenatal Antiepileptic Drug exposure. DevelopMental NeuroPsychology, 37, 1-29.
• Ng, F., Berk, M., Sachs, G.S., Wilting, I., Ferrier, I.N., Cassidy, F., e.a. (2009). The International Society of Bipolar disorders (ISBD) consensus guidelines for safety monitoring of bipolar disorder treatments. Bipolar Disorders, 11, 559-595.
• Ngyen, H.T.T., Sharma, V., & McIntyre, R.S. (2009). Teratogenesis associated with antibipolar agents. Advances in Therapy, 26, 281-294.
• NHG (2012). Multidisciplinaire richtlijn polyfarmacie bij ouderen. Utrecht: Nederlands Huisartsen Genootschap.
• NICE (2005). Depression in children and young people: Identification and management in primary, community and secondary care [guidelines]. London: National Institute for Health and Clinical Excellence; 2012. Available from: http://www.nice.org.uk/guidance/cg28.
• NVOG (2012). Richtlijn: SSRI-gebruik in de zwangerschap en tijdens de lactatie. Utrecht: Nederlandse Vereniging voor Obstetrie en Gynaecologie.
• Pappadopulos, E., Newcomer, J.W., & Kolluri, S. (2012). Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials. Journal of Clinical Psychiatry, 73, e742-e748.
• Patrizi, A., Savoia, F., Negosanti, F., Posar, A., Santucci, M., & Neri, I. (2005). Telogen effluvium caused by magnesium valproate and lamotrigine. Acta Dermato-venereologica, 85, 77-78.
• Perucca, E., Aldenkamp, A., Tallis, R., & Krämer, G. (2006). Role of valproate across the ages: Treatment of epilepsy in the elderly. Acta Neurologica Scandinavica Supplementum, 184, 28-37.
• Pijl, H., & Meinders, A.E. (1996). Bodyweight change as an adverse effect of drug treatment: Mechanisms and management. Drug Safety, 14, 329-342.
• Ramsay, R.E., Rowan, A.J., & Pryor, F.M. (2004). Special considerations in treating the elderly patient with epilepsy. Neurology, 62(Suppl 2), S24-S29.
• Rej, S., Herrmann, N., & Shulman, K. (2012). The effects of lithium on renal function in older adults: a systematic review. Journal of Geriatric Psychiatry and Neurology, 25, 51-61.
• Remmer, H.I., & Falk, W.E. (1986). Successful treatment of lithium-induced acne. Journal of Clinical Psychiatry, 47, 48.
• Sajatovic, M., Madhusoodanan, S., & Coconcea, N. (2005). Managing bipolar disorder in the elderly: defining the role of the newer agents [Review]. Drugs and Aging, 22, 39-54.
• Schneeweiss, S., Setoguchi, S., Brookhart, A., Dormuth, C., & Wang, P.S. (2007). Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal, 176, 627-632.
• Schouws, S.N., Stek, M.L., Comijs, H.C., & Beekman, A.T. (2010). Risk factors for cognitive impairment in elderly bipolar patients. Journal of Affective Disorders, 125, 330-335.
• Senturk, V., Goker, C., Bilgic, A., Olmez, S., Tugcu, H., Oncu, B., e.a. (2007). Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate. Bipolar Disorders, 9(Suppl 1), 136-44.
• Setoguchi, S., Wang, P.S., Alan Brookhart, M., Canning, C.F., Kaci, L., & Schneeweiss, S. (2008). Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. Journal of the American Geriatrics Society, 56, 1644-1650.
• Shan, J.C., Hsieh, M.H., Liu, C.C., Wen, C.C., & Liu, C.M. (2009). Clinical alertness to valproic acid-induced hyperammonemia: two case reports. Journal of Psychopharmacology, 24, 943-945.
• Shon, S.H., Joo, Y., Lee, J.S., & Kim, H.W. (2014). Lamotrigine treatment of adolescents with unipolar and bipolar depression: a retrospective chart review. Journal of Child and Adolescent Psychopharmacology, 24, 285-287.
• Sirmans, S.M., & Pate, K.A. (2013). Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical Epidemiology, 6, 1-13.
• Smaldone, M., Sukkarieh, T., Reda, A., & Khan, A. (2004). Epilepsy and erectile dysfunction: a review. Seizure, 13, 453-459.
• Sobotka, J.L., Alexander, B., & Cook, B.L. (1990). A review of carbamazepine’s hematologic reactions and monitoring recommendations. DICP, 24, 1214-9.
• Stoll, A.L., Vucovic, A., & McElroy, S.L. (1991). Histamine2-receptor antagonists for the treatment of valproate-induced gastrointestinal distress. Annals of Clinical Psychiatry, 3, 301-304.
• Tengstrand, M., Star, K., Puijenbroek, E.P. van, & Hill, R. (2010). Alopecia in association with lamotrigine use: an analysis of individual case safety reports in a global database. Drug Safety, 33, 653-658.
• Tomson, T., & Battino, D. (2008). Teratogenic effects of antiepileptic drugs. Seizure, 17, 166-171.
• Torrent, C., Amann, B., Sanchez-Moreno, J., Colom, F., Reinares, M., Comes, M., e.a. (2008). Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatrica Scandinavica, 118, 4-18.
• Trimbos-instituut (2008). Addendum ouderen bij MDR depressie [addendum bij de Multidisciplinaire richtlijn depressie bij volwassenen]. Utrecht: Trimbosinstituut.
• Trimbos-instituut (2009). Multidisciplinaire richtlijn depressie bij jeugd, Addendum [addendum bij de Multidisciplinaire richtlijn depressie bij volwassenen]. Utrecht: Trimbos-instituut.
• Wang, P.S., Schneeweiss, S., Avorn, J., Fischer, M.A., Mogun, H., Solomon, D.H., e.a. (2005). Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine, 353, 2335-2341.
• Wingo, A.P., Harvey, P.D., & Baldessarini, R.J. (2009). Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disorders, 11, 113-25.
• Yeung, C.K., & Chan, H.H. (2004). Cutaneous adverse effects of lithium: epidemiology and management. American Journal of Clinical Dermatology, 5, 3-8.
• Yonkers, K. A., Wisner, K. L., Stowe, Z., Leibenluft, E., Cohen, L., Miller, L., e.a. (2004). Management of bipolar disorder during pregnancy and the postpartum period. American Journal of Psychiatry, 161, 608-20.
• Young, R.C. (2005). Evidence-based pharmacological treatment of geriatric bipolar disorder. Psychiatric Clinics of North America, 28, 837-869.
• Zimmermann, U., Rechlin, T., Plaskacewicz, G.J., Barocka, A., Wildt, L., & Kaschka, W.P. (1997). Effect of naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study. Biological Psychiatry, 41, 747-749.